![Sarah Bridges](https://profiles-cardiff.imgix.net/attachments/638?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Mrs Sarah Bridges
Rheolwr Treial
- BridgesSE@caerdydd.ac.uk
- Neuadd Meirionnydd, Ystafell 6ed Llawr, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS
Trosolwyg
Fi yw'r Rheolwr Treial ar gyfer treial SCOPE2, astudiaeth aml-ganolfan ar hap Cam II/III o uwchgyfeirio dosau radiotherapi mewn cleifion â chanser oesoffagaidd a gaiff ei drin â chemoradiotherapi diffiniol (gydag astudiaeth Cyfnod II wedi'i hymgorffori o sgan PET ychwanegol sy'n llywio trefn cemotherapi mewn cleifion ag ymateb cynnar gwael). Mae SCOPE2 yn agored ac yn recriwtio ar hyn o bryd.
Rwyf hefyd yn rheoli treial FOLFERA, astudiaeth ar hap Cam II gaeedig o ychwanegu antagonist derbynnydd endothelin i'r regimen cemotherapi FOLFIRI mewn cleifion â chanser colorectal metastatig ar ôl methiant regimen sy'n cynnwys oxaliplatin.
Yn hydref 2020 roeddwn yn Rheolwr Treial ar gyfer astudiaeth brechlyn Covid-19 Novavax yn ei gyfleuster yng Ngogledd Cymru mewn cydweithrediad ag Iechyd Cyhoeddus Cymru, Ymchwil Iechyd a Gofal Cymru, a Bwrdd Iechyd Prifysgol Betsi Cadwaladr. Rwyf hefyd yn ymwneud â datblygu astudiaeth canser yr ymennydd ochr yn ochr â chydweithwyr yn Imperial, ac rwy'n gyd-Brif Ymchwilydd Talking Trials, prosiect Prawf o Gysyniad Ymgysylltu â'r Cyhoedd Ymddiriedolaeth Wellcome sy'n archwilio canfyddiadau o dreialon clinigol ymhlith y rhai o gefndiroedd lleiafrifoedd ethnig sy'n byw yng Nglanyrafon, Caerdydd.
Cyhoeddiad
2023
- Mukherjee, S. et al. 2023. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61, article number: 102059. (10.1016/j.eclinm.2023.102059)
- Bridges, S. et al. 2023. Talking Trials: An arts‐based exploration of attitudes to clinical trials amongst minority ethnic members of the South Riverside Community of Cardiff. Health Expectations 26(3), pp. 1236-1245. (10.1111/hex.13740)
2022
- Bridges, S. et al. 2022. SCOPE 2 – Still answering the unanswered questions in oesophageal radiotherapy? SCOPE 2: a Randomised phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded phase II trial for patients with a poor early response using positron emission tomography/computed tomography. Clinical Oncology 34(7), pp. E269-E280. (10.1016/j.clon.2022.03.019)
2015
- Hurt, C. N. et al. 2015. Health-related quality of life in SCALOP, a randomized Phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 93(4), pp. 810-818.
2013
- Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87(2), pp. S306. (10.1016/j.ijrobp.2013.06.804)
2010
- Mukherjee, S. et al. 2010. A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. American Journal of Clinical Oncology 28
Erthyglau
- Mukherjee, S. et al. 2023. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61, article number: 102059. (10.1016/j.eclinm.2023.102059)
- Bridges, S. et al. 2023. Talking Trials: An arts‐based exploration of attitudes to clinical trials amongst minority ethnic members of the South Riverside Community of Cardiff. Health Expectations 26(3), pp. 1236-1245. (10.1111/hex.13740)
- Bridges, S. et al. 2022. SCOPE 2 – Still answering the unanswered questions in oesophageal radiotherapy? SCOPE 2: a Randomised phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded phase II trial for patients with a poor early response using positron emission tomography/computed tomography. Clinical Oncology 34(7), pp. E269-E280. (10.1016/j.clon.2022.03.019)
- Hurt, C. N. et al. 2015. Health-related quality of life in SCALOP, a randomized Phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 93(4), pp. 810-818.
- Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87(2), pp. S306. (10.1016/j.ijrobp.2013.06.804)
- Mukherjee, S. et al. 2010. A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. American Journal of Clinical Oncology 28
- Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87(2), pp. S306. (10.1016/j.ijrobp.2013.06.804)
- Mukherjee, S. et al. 2010. A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. American Journal of Clinical Oncology 28